Cyclin D1 harboring the T286I mutation promotes oncogenic activation in endometrial cancer

Oncology Reports

Volumn 30, Issue 2, 2013, Pages 584-588

  Ikeda, Yuji ^a   Oda, Katsutoshi ^a   Hiraike Wada, Osamu ^a   Koso, Takahiro ^a   Miyasaka, Aki ^a   Kashiyama, Tomoko ^a   Tanikawa, Michihiro ^a   Sone, Kenbun ^a   Nagasaka, Kazunori ^a   Maeda, Daichi ^a   Kawana, Kei ^a   Nakagawa, Shunsuke ^b   Fukayama, Masashi ^a   Tetsu, Osamu ^c   Fujii, Tomoyuki ^a   Yano, Tetsu ^a   Kozuma, Shiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cyclin D1; Endometrial cancer; Mutation; T286I

Indexed keywords

CYCLIN D1; ISOLEUCINE; MUTANT PROTEIN; THREONINE;

ADULT; AGED; AMINO ACID SUBSTITUTION; ARTICLE; CCND1 GENE; CELL NUCLEUS; CELL PROLIFERATION; CODON; CONTROLLED STUDY; EMBRYO; ENDOMETRIUM CANCER; FEMALE; GENE; GENE ACTIVATION; GENE EXPRESSION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; ONCOGENE K RAS; ONCOGENIC ACTIVATION; PIK3CA GENE; PRB GENE; PRIORITY JOURNAL; PROTEIN FUNCTION; PTEN GENE; WILD TYPE;

ADULT; AGED; AGED, 80 AND OVER; CARCINOGENESIS; CELL PROLIFERATION; CYCLIN D1; ENDOMETRIAL NEOPLASMS; FEMALE; GENES, RAS; HEK293 CELLS; HUMANS; MIDDLE AGED; MUTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PTEN PHOSPHOHYDROLASE; RAS PROTEINS; RETINOBLASTOMA PROTEIN;

EID: 84879662875     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2013.2515     Document Type: Article

References (31)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin 60: 277-300, 2010.
2. McMeekin DS, Filiaci VL, Thigpen JT, Gallion HH, Fleming GF and Rodgers WH: The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study. Gynecol Oncol 106: 16-22, 2007. (Pubitemid 46898605)
3. Oda K, Stokoe D, Taketani Y and McCormick F: High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669-10673, 2005. (Pubitemid 41713332)
4. Oda K, Okada J, Timmerman L, et al: PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68: 8127-8136, 2008.
5. Shoji K, Oda K, Nakagawa S, et al: The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145-148, 2009.
6. Murayama-Hosokawa S, Oda K, Nakagawa S, et al: Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene 29: 1897-1908, 2010.
7. Ikeda Y, Oda K, Nakagawa S, et al: Genome-wide single nucleotide polymorphism arrays as a diagnostic tool in patients with synchronous endometrial and ovarian cancer. Int J Gynecol Cancer 22: 725-731, 2012.
8. Malumbres M and Barbacid M: Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9: 153-166, 2009.
9. Kato J, Matsushime H, Hiebert SW, Ewen ME and Sherr CJ: Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 7: 331-342, 1993. (Pubitemid 23139228)
10. Lundberg AS and Weinberg RA: Functional inactivation of the retinoblastoma protein requires sequential modification by at least two distinct cyclin-cdk complexes. Mol Cell Biol 18: 753-761, 1998. (Pubitemid 28063408)
11. Tetsu O and McCormick F: β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398: 422-426, 1999.
12. Albanese C, Johnson J, Watanabe G, et al: Transforming p21ras mutants and c-Ets-2 activate the cyclin D1 promoter through distinguishable regions. J Biol Chem 270: 23589-23597, 1995.
13. Musgrove EA, Caldon CE, Barraclough J, Stone A and Sutherland RL: Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11: 558-572, 2011.
14. Knudsen KE, Diehl JA, Haiman CA and Knudsen ES: Cyclin D1: polymorphism, aberrant splicing and cancer risk. Oncogene 25: 1620-1628, 2006.
15. Solomon DA, Wang Y, Fox SR, et al: Cyclin D1 splice variants. Differential effects on localization, RB phosphorylation, and cellular transformation. J Biol Chem 278: 30339-30347, 2003. (Pubitemid 36962428)
16. Lu F, Gladden AB and Diehl JA: An alternatively spliced cyclin D1 isoform, cyclin D1b, is a nuclear oncogene. Cancer Res 63: 7056-7061, 2003. (Pubitemid 37413439)
17. Kang S, Kim JW, Park NH, Song YS, Kang SB and Lee HP: Cyclin D1 polymorphism and the risk of endometrial cancer. Gynecol Oncol 97: 431-435, 2005. (Pubitemid 40614886)
18. Benzeno S, Lu F, Guo M, et al: Identification of mutations that disrupt phosphorylation-dependent nuclear export of cyclin D1. Oncogene 25: 6291-6303, 2006. (Pubitemid 44564745)
19. Moreno-Bueno G, Rodriguez-Perales S, Sanchez-Estevez C, et al: Cyclin D1 gene (CCND1) mutations in endometrial cancer. Oncogene 22: 6115-6118, 2003. (Pubitemid 37175891)
20. Minaguchi T, Yoshikawa H, Oda K, et al: PTEN mutation located only outside exons 5, 6, and 7 is an independent predictor of favorable survival in endometrial carcinomas. Clin Cancer Res 7: 2636-2642, 2001. (Pubitemid 32911365)
21. Tanikawa M, Wada-Hiraike O, Nakagawa S, et al: Multifunctional transcription factor TFII-I is an activator of BRCA1 function. Br J Cancer 104: 1349-1355, 2011.
22. Alt JR, Cleveland JL, Hannink M and Diehl JA: Phosphorylation-dependent regulation of cyclin D1 nuclear export and cyclin D1-dependent cellular transformation. Genes Dev 14: 3102-3114, 2000. (Pubitemid 32015129)
23. Gladden AB, Woolery R, Aggarwal P, Wasik MA and Diehl JA: Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene 25: 998-1007, 2006. (Pubitemid 43277008)
24. Hall M and Peters G: Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. Adv Cancer Res 68: 67-108, 1996. (Pubitemid 26099813)
25. Sherr CJ: Cancer cell cycles. Science 274: 1672-1677, 1996.
26. Waf1/Cip1 expression is predictive of poor clinical outcome in serous epithelial ovarian cancer. Clin Cancer Res 10: 5168-5177, 2004.
27. Ogino S, Nosho K, Irahara N, et al: A cohort study of cyclin D1 expression and prognosis in 602 colon cancer cases. Clin Cancer Res 15: 4431-4438, 2009.
28. Bodrug SE, Warner BJ, Bath ML, Lindeman GJ, Harris AW and Adams JM: Cyclin D1 transgene impedes lymphocyte maturation and collaborates in lymphomagenesis with the myc gene. EMBO J 13: 2124-2130, 1994. (Pubitemid 24139725)
29. Lovec H, Grzeschiczek A, Kowalski MB and Moroy T: Cyclin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice. EMBO J 13: 3487-3495, 1994. (Pubitemid 24246185)
30. Lovec H, Sewing A, Lucibello FC, Muller R and Moroy T: Oncogenic activity of cyclin D1 revealed through cooperation with Ha-ras: link between cell cycle control and malignant transformation. Oncogene 9: 323-326, 1994. (Pubitemid 24020966)
31. Uchimaru K, Endo K, Fujinuma H, Zukerberg L, Arnold A and Motokura T: Oncogenic collaboration of the cyclin D1 (PRAD1, bcl-1) gene with a mutated p53 and an activated ras oncogene in neoplastic transformation. Jpn J Cancer Res 87: 459-465, 1996. (Pubitemid 26182315)